CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 102 enrolled
Drug / intervention
GnRh (Leuprolide) +2 moredrug
Likely dose
Testosterone Gel 7.5Gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00587431
NCT00587431Phase 2Completed
CompareCT.gov

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center·interventional·Posted Jan 7, 2008·Updated Nov 7, 2023

In Brief

A Phase 2 clinical trial evaluating GnRh (Leuprolide), Testosterone Gel, and 1 other intervention for Prostate Cancer. Completed, enrolled 102 participants across 1 site.

Detailed Summary

We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 7, 2008
Enrollment StartJul 1, 2003
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 18.5 years ago

Interventions

GnRh (Leuprolide)drug

Leuprolide LUPRON

Testosterone Geldrug

Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)

Docetaxeldrug

70 mg/m2 given on day o1 of each 3 week cycle